Surrozen Shares Are Trading Higher After the Company Announced It Earned a $10 Million Payment as Part of a Collaboration With Boehringer That Is Advancing the Development of SZN-413 for Retinal Vascular Diseases.

BenzingaSep 24 14:46 ET

Express News | Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

ReutersSep 24 08:30 ET

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky

Yahoo FinanceAug 15 06:21 ET

Surrozen GAAP EPS of -$7.99

Seeking AlphaAug 13 11:00 ET

Express News | Surrozen Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Adjusted EPS Results

BenzingaAug 13 09:50 ET

Express News | Surrozen Q2 2024 Adj EPS $(7.99) Misses $(2.79) Estimate

BenzingaAug 12 16:22 ET